Abstract
Congenital nephrotic syndrome (CNS) refers to a disease presenting with massive proteinuria in association with hypoalbuminemia, hyperlipidemia, and edema at birth or within the first three months of life. In the past, most children with CNS had extremely poor prognosis and succumbed to various complications, usually within the first 6 months. Recent advancements in protein supplementation and nutritional support, renal replacement therapy and renal transplantation in infancy, render these patients to have much better outcomes [1-5]. However, there are still many hurdles in the management of this disease. Thromboembolism is an uncommon, yet important complication which the healthcare givers must be aware of. This article reviews the challenges in the management of the thrombotic complications with special emphasis on the unique characteristics of the newborn hemostasis system and anti-thrombin (AT) depletion in nephrotic syndrome. Due to the relatively low incidence of CNS in children and scarce information in the literature on the optimal management of the thromboembolic complications, most of the recommendations are based on the authors’ experience.
Keywords: Congenital nephrotic syndrome, warfarin, thrombosis. neonates, children, management.
Current Pediatric Reviews
Title:Thrombotic Complications of Neonates and Children with Congenital Nephrotic Syndrome
Volume: 10 Issue: 3
Author(s): Keith K. Lau, Howard H. Chan, Patti Massicotte and Anthony K. Chan
Affiliation:
Keywords: Congenital nephrotic syndrome, warfarin, thrombosis. neonates, children, management.
Abstract: Congenital nephrotic syndrome (CNS) refers to a disease presenting with massive proteinuria in association with hypoalbuminemia, hyperlipidemia, and edema at birth or within the first three months of life. In the past, most children with CNS had extremely poor prognosis and succumbed to various complications, usually within the first 6 months. Recent advancements in protein supplementation and nutritional support, renal replacement therapy and renal transplantation in infancy, render these patients to have much better outcomes [1-5]. However, there are still many hurdles in the management of this disease. Thromboembolism is an uncommon, yet important complication which the healthcare givers must be aware of. This article reviews the challenges in the management of the thrombotic complications with special emphasis on the unique characteristics of the newborn hemostasis system and anti-thrombin (AT) depletion in nephrotic syndrome. Due to the relatively low incidence of CNS in children and scarce information in the literature on the optimal management of the thromboembolic complications, most of the recommendations are based on the authors’ experience.
Export Options
About this article
Cite this article as:
Lau K. Keith, Chan H. Howard, Massicotte Patti and Chan K. Anthony, Thrombotic Complications of Neonates and Children with Congenital Nephrotic Syndrome, Current Pediatric Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/1573396309666131209210310
DOI https://dx.doi.org/10.2174/1573396309666131209210310 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Secondary Prevention of Ischemic Stroke
Current Drug Targets The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part I: Epidemiology, Clinical Aspects and Diagnostic Options
Current Cardiology Reviews Lupus Nephritis: A Treatment Update
Current Clinical Pharmacology Current Therapeutic Strategies and Future Perspectives for the Prevention of Arterial Thromboembolism: Focus on Atrial Fibrillation
Current Pharmaceutical Design Novel uses of Imaging in AF Ablation
Recent Patents on Cardiovascular Drug Discovery Editorial (Thematic Issue: Novel Oral Anticoagulants; “All that Glitters is not Gold, or is it?”)
Cardiovascular & Hematological Agents in Medicinal Chemistry A Survey on Synthesis Processes of Structured Materials for Biomedical Applications: Iron-based Magnetic Nanoparticles, Polymeric Materials and Polymerization Processes
Current Pharmaceutical Design Safety of Dabigatran in an Elderly Population: Single Center Experience in Italy
Current Drug Safety Emerging Anticoagulant Therapies for Atrial Fibrillation: New Options, New Challenges
Current Medicinal Chemistry Emerging Therapy Options in Heparin-Induced Thrombocytopenia
Cardiovascular & Hematological Agents in Medicinal Chemistry Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab
Current Cancer Therapy Reviews The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Identification of Candidate Biomarkers of Acute Aortic Dissection
Recent Patents on DNA & Gene Sequences Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Current Vascular Pharmacology Approaches for the Cure of Type 1 Diabetes by Cellular and Gene Therapy
Current Gene Therapy Multimodality Imaging in Acute Ischemic Stroke
Current Medical Imaging